BitMine Immersion Technologies (BMNR), the largest corporate holder of Ethereum, has increased its ETH holdings. According to a press release, the company purchasedBitMine Immersion Technologies (BMNR), the largest corporate holder of Ethereum, has increased its ETH holdings. According to a press release, the company purchased

BitMine Boosts Ethereum Holdings with Over $117M Latest Purchase

2026/01/27 01:40
2 min read

BitMine Immersion Technologies (BMNR), the largest corporate holder of Ethereum, has increased its ETH holdings. According to a press release, the company purchased 40,302 ETH worth $117.2 million between January 20 and January 25, 2026. 

The latest acquisition brings BitMine’s total ETH stash to 4,243,338 ETH. At current market prices, the holdings are valued at approximately $12.33 billion. With this, the company moves closer to its goal of securing 5% of Ethereum’s supply. 

Bitmine Tops Its Ethereum Stash 

BitMine’s push to increase its Ethereum position follows a string of incremental purchases throughout late 2025 and early 2026. According to recent market data, Bitmine’s ETH holdings now top 4.24 million coins, representing roughly 3.52% of the total circulating Ethereum supply. These holdings also contribute significantly to the company’s crypto and cash portfolio, which is valued at over $12.8 billion.

Of this total, 2,009,267 ETH worth $5.7 billion is staked across three providers as BitMine advances its upcoming Made in America Validator Network (MAVAN). This figure represents an increase of 171,264 ETH over the past week and remains a portion of BitMine’s 4.24 million ETH treasury. Tom Lee, BitMine’s spokesperson, stated that the company has staked more ETH than any other entity in the world.

Wall Street Embraces Crypto

BitMine’s latest Ethereum purchase reflects more than balance-sheet expansion; it signals growing institutional confidence in digital assets. Tom Lee highlighted conversations from a high-level meeting between global policymakers and business leaders held last week. 

According to Lee, one key takeaway stood out clearly: Wall Street has now embraced crypto and blockchain assets. Traditional finance no longer views digital assets as a niche idea, but as a natural shift toward blending traditional markets with blockchain technology.

At the same time, Bitmine continues to diversify its growth strategy beyond digital assets alone. Earlier this month, the company invested $200 million into Beast Industries to support its expansion and potential DeFi initiatives.

The post BitMine Boosts Ethereum Holdings with Over $117M Latest Purchase appeared first on CoinTab News.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26